Evidence map›Paper›PMID 31648079›Full record

ArticleBone2020

Combination therapy in the Col1a2

Shannon Kaupp, Dan J Horan, Kyung-Eun Lim, Henry A Feldman, Alexander G Robling, Matthew L Warman, Christina M Jacobsen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Characterization of a Novel Col1a1Calcified tissue international · 2025
    Article
  2. Article
  3. 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  4. Targeting TGF-β for treatment of osteogenesis imperfecta.The Journal of clinical investigation · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shannon KauppOrthopedic Research Laboratories, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.
Dan J HoranDepartment of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA.
Kyung-Eun LimDepartment of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA.
Henry A FeldmanInstitutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA.
Alexander G RoblingDepartment of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA.
Matthew L WarmanOrthopedic Research Laboratories, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA; Department of Genetics, Harvard Medical School, Boston, MA, USA.
Christina M JacobsenDivisions of Endocrinology and Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: Christina.jacobsen@childrens.harvard.edu.
Boston Children's Hospital · USIndiana University – Purdue University Indianapolis · US

Funding

The LRP5 Pathway and Osteoblast Function In Osteogenesis ImperfectaR01AR071342 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI JACOBSEN, CHRISTINA MARIE · 2018 to 2022
$3.0M
Targeting the Lrp5 Pathway To Increase Bone Strength In Osteogenesis ImperfectaK08AR063813 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI JACOBSEN, CHRISTINA MARIE · 2013 to 2017
$706k
The Efficacy of combination therapy in Osteogenesis ImperfectaR21AR067388 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI WARMAN, MATTHEW L · 2015 to 2016
$428k
NIAMS NIH HHS K08 AR063813NIAMS NIH HHS R01 AR071342NIAMS NIH HHS R21 AR067388
6 · The paper itself

Abstract

Enhancing LRP5 signaling and inhibiting TGFβ signaling have each been reported to increase bone mass and improve bone strength in wild-type mice. Monotherapy targeting LRP5 signaling, or TGFβ signaling, also improved bone properties in mouse models of Osteogenesis Imperfecta (OI). We investigated whether additive or synergistic increases in bone properties would be attained if enhanced LRP5 signaling was combined with TGFβ inhibition. We crossed an Lrp5 high bone mass (HBM) allele (Lrp5

Indexed as

Osteogenesis ImperfectaAnimalsCancellous BoneCollagen Type ICortical BoneDisease Models, AnimalHumansLow Density Lipoprotein Receptor-Related Protein-5MiceSignal TransductionTransforming Growth Factor betaCOL1A2 protein, humanCol1a2 protein, mouseCollagen Type ILow Density Lipoprotein Receptor-Related Protein-5LRP5 protein, humanLrp5 protein, mouseTransforming Growth Factor betaLRP5Osteogenesis ImperfectaSclerostinTGFβWNT

Identifiers

PMID31648079
PMCPMC7232829
OpenAlexW2981917279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.